It’s Brain Awareness Week and we are celebrating the scientists, innovators, and clinicians dedicated to improving brain health and transforming lives including our partners and community Members including:? Neurexis Therapeutics: Developing novel treatments to combat brain injuries and neurological disorders. CU Research Imaging Center (CU-RIC): Leading advanced neuroimaging research to deepen our understanding of the brain. #BrainAwarenessWeek #Neuroscience #InnovationCommunity #BrainHealth #NeuroTech?
Neurexis Therapeutics
生物技术研究
Aurora，Colorado 213 位关注者
Neuroprotective Innovation for Human Health
关于我们
Neurexis is developing an optimized peptide with demonstrated efficacy and safety in small and large animal models of global cerebral ischemia.
- 网站
-
https://neurexistherapeutics.com/
Neurexis Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Aurora，Colorado
- 类型
- 私人持股
地点
-
主要
获取路线
12635 E Montview Blvd
Suite 100
US，Colorado，Aurora，80045
Neurexis Therapeutics员工
动态
-
Explore the annual report featuring Neurexis Therapeutics
The VIC Tech 2024 annual report executive summary is here! Despite a challenging venture capital landscape for early-stage life sciences, VIC Tech portfolio companies had their second-highest fundraising year ever in 2024. This success included VIC Tech's own VIC Investor Network reaching record investment levels, highlighting strong stakeholder confidence and expanding industry collaborations. Explore all the details below. https://hubs.ly/Q038c_sY0
-
We are pleased to share that Neurexis Therapeutics just secured a $3M NIH grant to advance our neuroprotective treatment for Global Cerebral Ischemia. This funding brings us closer to clinical trials for our lead compound, tatCN19o, offering hope to those affected by ischemic brain injuries. National Institute of Neurological Disorders and Stroke (NINDS) The National Institutes of Health
-
We are excited to share our 2024 progress in the VIC Tech mid-year update. https://lnkd.in/gr3Ys5dr
Our mid-year update showcases a remarkable first half of 2024, with substantial product development and commercialization progress, new private investments, and regulatory advancement. We also welcomed our first institutional investor to the VIC Investor Network, marking a significant milestone. Read the full update to discover our portfolio companies' exciting strides and the promising outlook for the remainder of the year. https://hubs.ly/Q02KCW9c0